BioXcel Therapeutics Inc BTAIQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.02
- Day Range
- $0.01–0.02
- 52-Week Range
- $0.01–2.46
- Bid/Ask
- — / —
- Shares Outstanding
- 31.31M
- Market Cap
- $469,582.49
- Volume/Avg
- 239,999 / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.46
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Valuation
|
Metric
|
BTAIQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.46 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BTAIQ
|
|---|---|
Quick Ratio | 0.09 |
Current Ratio | 0.21 |
Interest Coverage | −3.17 |
Quick Ratio
BTAIQ
Profitability
|
Metric
|
BTAIQ
|
|---|---|
Return on Assets (Normalized) | −166.10% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,096.22% |
Return on Assets
BTAIQ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|?SY^<&xC | LOCK|>&B>n | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|dvpr#Bg% | LOCK|Tkb?X | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|<t?X&$H | LOCK|$% | $45B | |||
| Zoetis Inc Class A
ZTS
| LOCK|kVtWK?? | LOCK|!RY | $33B | |||
| Viatris Inc
VTRS
| LOCK|?Xml<$? | LOCK|!# | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|r! | LOCK|<# | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|#yGb?qX | LOCK|rP | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|j^!$>@d | LOCK|kbK | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|@Znt^y$ | LOCK|$#Wl | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|Mvr&&Q | LOCK|$Lf | $2B |
United States